查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1279849

2023-2030年全球急性髓性白血病市场规模研究与预测，按化疗方法（阿糖胞苷、蒽环类药物、烷化剂、抗代谢药、酪氨酸激酶抑制剂、激素疗法、其他化疗方法）和区域分析

Global Acute Myeloid Leukemia Market Size Study & Forecast, By Chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal Therapy, Other Chemotherapies), and Regional Analysis, 2023-2030
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3个工作天内

价格

急性骨髓性白血病（AML）是一种血癌和骨髓中不成熟白细胞过多的形式。它的特点是不成熟的骨髓细胞迅速增殖，这是一种负责对抗感染的白血球类型。这些不成熟的细胞在急性髓系白血病患者的骨髓中聚集，阻碍健康血细胞的形成，从而导致症状和问题。急性骨髓性白血病发病率的增加，新型疗法的不断推出，对精准医疗的重视，免疫疗法的采用激增，以及医疗开支的增加，是导致全球市场需求的主要因素。

此外，老年人口的增加也是全球市场增长的一个催化因素。根据美国癌症协会的数据，急性髓细胞白血病通常发生在老年人群中，45岁之前并不常见。此外，AML的平均年龄接近68岁。世界卫生组织（WHO）报告说，预计老龄人口的数量将从2020年的10亿增加到2030年的15亿，全世界60岁以上的人中有1人。因此，快速增长的老年人口更容易受到急性骨髓性白血病的影响，这为市场增长创造了有利可图的机会。此外，药理学和分子生物学的不断进步促进了药物开发，以及对研究和开发的投资不断增加，在预测的几年里呈现各种有利可图的机会。例如，2022年5月，美国食品和药物管理局宣布，他们批准了Tibsovo，Servier Pharmaceuticals LLC的ivosidenib与阿扎胞苷的混合物（注射用阿扎胞苷）用于新诊断的急性骨髓性白血病（AML）。此外，它涉及到由FDA批准的测试确定的易感IDH1突变，适用于75岁及以上的成人或有妨碍强化诱导化疗的合并症。然而，在整个2023-2030年的预测期内，对药物和与化疗有关的并发症的严格规定限制了市场的增长。

全球急性髓性白血病市场研究考虑的主要地区包括亚太、北美、欧洲、拉丁美洲、中东和非洲。由于急性骨髓性白血病病例的发病率不断增加，技术进步不断提高，以及越来越重视以病人为中心的方法，北美在2022年主导了市场。美国癌症协会表示，在2023年，大约有59,610个白血病新病例和23,710个白血病死亡病例。而在预测期内，亚太地区预计将以最高的年复合增长率增长，原因是政府的有利倡议、开展的临床试验数量不断增加、医疗保健支出不断增加以及分子诊断技术的不断进步等因素。

该研究的目的是确定近年来不同领域和国家的市场规模，并对未来几年的价值进行预测。该报告旨在将研究涉及的国家内的行业的质量和数量方面都纳入其中。

该报告还提供了关于关键方面的详细信息，如驱动因素和挑战，这将确定市场的未来增长。此外，它还纳入了微观市场的潜在机会，供利益相关者投资，并详细分析了竞争格局和主要参与者的产品。.

目录

第一章：执行摘要

  • 市场简介
  • 2020-2030年全球和细分市场的估计和预测
    • 2020-2030年急性髓性白血病市场，按地区划分
    • 2020-2030年，急性髓系白血病市场，按化疗方法划分
  • 主要趋势
  • 估算方法
  • 研究假设

第二章：全球急性骨髓性白血病市场的定义和范围

  • 本研究的目的
  • 市场定义和范围
    • 行业演变
    • 研究的范围
  • 研究考虑的年份
  • 货币转换率

第三章：全球急性髓系白血病市场动态

  • 急性骨髓性白血病市场影响分析（2020-2030）。
    • 市场驱动力
      • 急性骨髓性白血病的发病率越来越高
      • 老年人口不断增加
    • 市场挑战
      • 严格的药物规定
      • 与化疗相关的并发症
    • 市场机会
      • 药理学和分子生物学的不断进步，促进药物开发
      • 增加研究和开发的投资

第四章：全球急性髓系白血病市场行业分析

  • 波特五力模型
    • 供应商的议价能力
    • 买方的讨价还价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 竞争性的竞争
  • 波特五力影响分析
  • PEST分析
    • 政治
    • 经济
    • 社会
    • 技术
    • 环境
    • 法律问题
  • 最佳投资机会
  • 最佳策略
  • COVID-19影响分析
  • 颠覆性趋势
  • 行业专家的观点
  • 分析师建议与结论

第五章：全球急性髓系白血病市场，按化疗方法划分

  • 市场简介
  • 全球急性髓性白血病市场，按化疗方法，表现 - 潜力分析
  • 2020-2030年全球急性骨髓性白血病市场按化疗方法的估计和预测
  • 急性骨髓性白血病市场，分项分析
    • 阿糖胞苷
    • 蒽环类药物
    • 烷基化药物
    • 抗代谢药
    • 酪氨酸激酶抑制剂
    • 激素治疗
    • 其他化疗药物

第六章：全球急性髓系白血病市场，区域分析

  • 最领先的国家
  • 新兴国家
  • 急性骨髓性白血病市场，区域市场简介
  • 北美洲
    • 美国
      • 2020-2030年化疗分类估计和预测
    • 加拿大
  • 欧洲急性髓系白血病市场简介
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 意大利
    • 欧洲其他地区
  • 亚太地区急性髓系白血病市场概况
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 韩国
    • 亚太其他地区
  • 拉丁美洲急性骨髓性白血病市场简介
    • 巴西
    • 墨西哥
  • 中东和非洲
    • 沙特阿拉伯
    • 南非
    • 中东和非洲其他地区

第七章 ：竞争情报

  • 主要公司SWOT分析
    • 公司1
    • 公司二
    • 公司3
  • 顶级市场战略
  • 公司简介
    • Novartis AG
      • 关键信息
      • 概况
      • 财务（取决于数据的可用性）
      • 产品摘要
      • 近期发展情况
    • Genmab AS
    • Otsuka Holdings Co. Ltd
    • Sanofi-Aventis (Genzyme Corporation)
    • Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • Sunesis Pharmaceuticals Inc.
    • Astellas Pharma Inc.
    • Oncolyze Inc.

第八章：研究过程

  • 研究过程
    • 资料探勘
    • 分析
    • 市场评估
    • 验证
    • 出版
  • 研究属性
  • 研究假设

Global Acute Myeloid Leukemia Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Acute Myeloid Leukemia (AML) is a form of blood cancer and bone marrow with excess immature white blood cells. It is characterized by the rapid proliferation of immature myeloid cells, which are a type of white blood cell responsible for fighting infections. These immature cells amass in the bone marrow in AML and obstruct the formation of healthy blood cells, resulting in symptoms and problems. The increasing prevalence of acute myeloid leukemia, the rising introduction of novel therapies, the rising emphasis on precision medicine, the surging adoption of immunotherapies, and increasing healthcare expenditure are the primary factors that are attributing to the market demand across the globe.

In addition, the rising geriatric population is acting as a catalyzing factor for market growth across the globe. According to the American Cancer Society, AML is usually occurred among the older population and is uncommon before the age of 45. Also, the average age for AML is nearly 68. The World Health Organization (WHO) reported that it is anticipated that the number of aging people increase from 1 billion in 2020 to 1.5 billion in 2030 which worldwide accounts for 1 in 6 people above 60. Hence, the rapidly growing geriatric population is more prone to be affected by acute myeloid leukemia, which is creating lucrative opportunities for market growth. Moreover, rising advancements in pharmacology and molecular biology to promote drug development, as well as the increasing investments in research and development are presenting various lucrative opportunities over the forecasting years. For instance, in May 2022, the FDA declared that they approved Tibsovo, Servier Pharmaceuticals LLC's ivosidenib in a mixture with azacitidine (azacitidine for injection) for novel diagnosed acute myeloid leukemia (AML). Additionally, it involves a susceptible IDH1 mutation identified by an FDA-approved test in adults aged 75 years and over or with comorbidities that prevent intensive induction chemotherapy. However, the stringent regulations on drugs and complications related to chemotherapy are restricting the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Acute Myeloid Leukemia Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing incidences of acute myeloid leukemia cases, rising technological advancements, and growing focus on patient-centric approaches. The American Cancer Society stated that in 2023, approximately 59,610 new cases of leukemia and 23,710 deaths from leukemia were recorded. Whereas, Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as favorable government initiatives, an increasing number of clinical trials conducted, rising healthcare expenditure, and growing advancements in molecular diagnostics.

Major market players included in this report are:

  • Novartis AG
  • Genmab AS
  • Otsuka Holdings Co. Ltd
  • Sanofi-Aventis (Genzyme Corporation)
  • Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Sunesis Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • Oncolyze Inc.

Recent Developments in the Market:

  • In January 2022, Oncolyze announced that OM-301, a medication used to treat acute myeloid leukaemia (AML), had been granted FDA orphan drug designation.
  • In December 2021, SNDX-5613, a highly specific oral menin inhibitor for the treatment of acute myeloid leukaemia (AML), was approved as an orphan drug by the European Commission.

Global Acute Myeloid Leukemia Market Report Scope:

  • Historical Data: - 2020 - 2021
  • Base Year for Estimation: - 2022
  • Forecast period: - 2023-2030
  • Report Coverage: - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: - Chemotherapy, Region
  • Regional Scope: - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Chemotherapy:

  • Cytarabine
  • Anthracycline Drugs
  • Alkylating Agents
  • Anti-metabolites
  • Tyrosine Kinase Inhibitors
  • Hormonal Therapy
  • Other Chemotherapies

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Acute Myeloid Leukemia Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Acute Myeloid Leukemia Market, by Chemotherapy, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Acute Myeloid Leukemia Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Acute Myeloid Leukemia Market Dynamics

  • 3.1. Acute Myeloid Leukemia Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing prevalence of acute myeloid leukemia
      • 3.1.1.2. Rising geriatric population
    • 3.1.2. Market Challenges
      • 3.1.2.1. Stringent regulations on drugs
      • 3.1.2.2. Complications related to chemotherapy
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Rising advancements in pharmacology and molecular biology to promote drug development
      • 3.1.3.2. Increasing investments in research and development

Chapter 4. Global Acute Myeloid Leukemia Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Acute Myeloid Leukemia Market, by Chemotherapy

  • 5.1. Market Snapshot
  • 5.2. Global Acute Myeloid Leukemia Market by Chemotherapy, Performance - Potential Analysis
  • 5.3. Global Acute Myeloid Leukemia Market Estimates & Forecasts by Chemotherapy 2020-2030 (USD Billion)
  • 5.4. Acute Myeloid Leukemia Market, Sub Segment Analysis
    • 5.4.1. Cytarabine
    • 5.4.2. Anthracycline Drugs
    • 5.4.3. Alkylating Agents
    • 5.4.4. Anti-metabolites
    • 5.4.5. Tyrosine Kinase Inhibitors
    • 5.4.6. Hormonal Therapy
    • 5.4.7. Other Chemotherapies

Chapter 6. Global Acute Myeloid Leukemia Market, Regional Analysis

  • 6.1. Top Leading Countries
  • 6.2. Top Emerging Countries
  • 6.3. Acute Myeloid Leukemia Market, Regional Market Snapshot
  • 6.4. North America Acute Myeloid Leukemia Market
    • 6.4.1. U.S. Acute Myeloid Leukemia Market
      • 6.4.1.1. Chemotherapy breakdown estimates & forecasts, 2020-2030
    • 6.4.2. Canada Acute Myeloid Leukemia Market
  • 6.5. Europe Acute Myeloid Leukemia Market Snapshot
    • 6.5.1. U.K. Acute Myeloid Leukemia Market
    • 6.5.2. Germany Acute Myeloid Leukemia Market
    • 6.5.3. France Acute Myeloid Leukemia Market
    • 6.5.4. Spain Acute Myeloid Leukemia Market
    • 6.5.5. Italy Acute Myeloid Leukemia Market
    • 6.5.6. Rest of Europe Acute Myeloid Leukemia Market
  • 6.6. Asia-Pacific Acute Myeloid Leukemia Market Snapshot
    • 6.6.1. China Acute Myeloid Leukemia Market
    • 6.6.2. India Acute Myeloid Leukemia Market
    • 6.6.3. Japan Acute Myeloid Leukemia Market
    • 6.6.4. Australia Acute Myeloid Leukemia Market
    • 6.6.5. South Korea Acute Myeloid Leukemia Market
    • 6.6.6. Rest of Asia Pacific Acute Myeloid Leukemia Market
  • 6.7. Latin America Acute Myeloid Leukemia Market Snapshot
    • 6.7.1. Brazil Acute Myeloid Leukemia Market
    • 6.7.2. Mexico Acute Myeloid Leukemia Market
  • 6.8. Middle East & Africa Acute Myeloid Leukemia Market
    • 6.8.1. Saudi Arabia Acute Myeloid Leukemia Market
    • 6.8.2. South Africa Acute Myeloid Leukemia Market
    • 6.8.3. Rest of Middle East & Africa Acute Myeloid Leukemia Market

Chapter 7. Competitive Intelligence

  • 7.1. Key Company SWOT Analysis
    • 7.1.1. Company 1
    • 7.1.2. Company 2
    • 7.1.3. Company 3
  • 7.2. Top Market Strategies
  • 7.3. Company Profiles
    • 7.3.1. Novartis AG
      • 7.3.1.1. Key Information
      • 7.3.1.2. Overview
      • 7.3.1.3. Financial (Subject to Data Availability)
      • 7.3.1.4. Product Summary
      • 7.3.1.5. Recent Developments
    • 7.3.2. Genmab AS
    • 7.3.3. Otsuka Holdings Co. Ltd
    • 7.3.4. Sanofi-Aventis (Genzyme Corporation)
    • 7.3.5. Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
    • 7.3.6. Pfizer Inc.
    • 7.3.7. F. Hoffmann-La Roche Ltd
    • 7.3.8. Sunesis Pharmaceuticals Inc.
    • 7.3.9. Astellas Pharma Inc.
    • 7.3.10. Oncolyze Inc.

Chapter 8. Research Process

  • 8.1. Research Process
    • 8.1.1. Data Mining
    • 8.1.2. Analysis
    • 8.1.3. Market Estimation
    • 8.1.4. Validation
    • 8.1.5. Publishing
  • 8.2. Research Attributes
  • 8.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Acute Myeloid Leukemia Market, report scope
  • TABLE 2. Global Acute Myeloid Leukemia Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Acute Myeloid Leukemia Market estimates & forecasts by Chemotherapy 2020-2030 (USD Billion)
  • TABLE 4. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 5. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 6. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. U.S. Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. U.S. Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 16. U.S. Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 17. Canada Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 18. Canada Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 19. Canada Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 20. UK Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 21. UK Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22. UK Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 23. Germany Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 24. Germany Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25. Germany Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 26. France Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 27. France Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28. France Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 29. Italy Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 30. Italy Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31. Italy Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 32. Spain Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 33. Spain Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34. Spain Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 35. RoE Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 36. RoE Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37. RoE Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 38. China Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 39. China Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40. China Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 41. India Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 42. India Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43. India Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 44. Japan Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 45. Japan Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46. Japan Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 47. South Korea Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 48. South Korea Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49. South Korea Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 50. Australia Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 51. Australia Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52. Australia Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 53. RoAPAC Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 54. RoAPAC Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55. RoAPAC Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 56. Brazil Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 57. Brazil Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58. Brazil Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 59. Mexico Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 60. Mexico Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61. Mexico Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 62. RoLA Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 63. RoLA Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64. RoLA Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 65. Saudi Arabia Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 66. South Africa Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67. RoMEA Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 68. List of secondary sources, used in the study of global Acute Myeloid Leukemia Market
  • TABLE 69. List of primary sources, used in the study of global Acute Myeloid Leukemia Market
  • TABLE 70. Years considered for the study
  • TABLE 71. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Acute Myeloid Leukemia Market, research methodology
  • FIG 2. Global Acute Myeloid Leukemia Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Acute Myeloid Leukemia Market, key trends 2022
  • FIG 5. Global Acute Myeloid Leukemia Market, growth prospects 2023-2030
  • FIG 6. Global Acute Myeloid Leukemia Market, porters 5 force model
  • FIG 7. Global Acute Myeloid Leukemia Market, pest analysis
  • FIG 8. Global Acute Myeloid Leukemia Market, value chain analysis
  • FIG 9. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Acute Myeloid Leukemia Market, regional snapshot 2020 & 2030
  • FIG 15. North America Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable